Search
forLearn
5 / 801 resultslearn AHK-Cu Copper Tripeptide
learn Setipiprant
learn Vascular Endothelial Growth Factor
learn Platelet-Rich Plasma
growth factors taken from your blood and injected into your scalp to stimulate hair
Research
5 / 138 results
research A case of acute vision loss due to retinal arteriolar occlusion after forehead injection of triamcinolone acetonide
A woman lost vision in one eye after a forehead injection, but prompt treatment led to partial vision recovery.
research Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report
Cyclosporine-A can cause serious blood clots in the brain, so patients need careful monitoring.
research Diverse origins of fibrinolytic enzymes: A comprehensive review
Exploring fermented foods from various regions can lead to discovering new fibrinolytic enzymes.
research In vitro thrombolytic activity of Moringa oleifera
Moringa oleifera may help prevent blood clots.
research Clinical and biological impact of the exposome on the skin
Environmental factors, hormones, nutrition, and stress all significantly affect skin health and aging.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.